Nectar Lifesciences Buyback 2025

Nectar Lifesciences Limited Buyback

Nectar Lifesciences Buyback 2025
Tender Offer

₹27.00

Buyback price per share

23 Dec, 2025

Last Date to buy shares

24 Dec, 2025

Record Date

31 Dec, 2025

Offer Opens

06 Jan, 2026

Offer Closes

06 Jan, 2026

Last Date for Tender Forms

13 Jan, 2026

Last Date for settlement of bids
About Nectar Lifesciences Limited Buyback Company

Nectar Lifesciences is a research-driven, fully integrated pharmaceutical company. Its core business revolves around the manufacturing of active pharmaceutical ingredients, mainly cephalosporin antibiotics and intermediates.
It has also ventured beyond APIs into contract manufacturing of FDFs/formulations such as tablets, capsules, suspensions, granules, and injectables. They also manufacture empty hard gelatin capsules (EHGCs) and have a presence in phytochemicals / menthol-based products.
The facilities of Nectar are state-of-the-art, comprising a total of 13 facilities across Punjab and Himachal Pradesh for oral and sterile drug productions, empty capsule production, and menthol or phytochemicals.
These plants meet the current global regulatory requirements for EHS/cGMP, besides approbations by the international regulatory authorities for export markets. This ensures that the quality of the product is guaranteed.

Read More
Nectar Lifesciences Limited Buyback Details
  • Security Name Nectar Lifesciences Limited
  • Buyback Price ₹27.00
  • Face Valuet ₹10.00
  • Listing at Group BSE, NSE
  • Lead Manager Master Capital Services Ltd.
  • Issue Size 3,00,00,000 (13.38 % of Total number of equity Shares)
  • Buyback Docs Letter Of Offer
Nectar Lifesciences Limited Buyback Ratio
Categoryy Entitlement Ratio of Buyback Shares Offered
Reserved Category for Small Shareholders /
General Category for all other Eligible Shareholders /
Nectar Lifesciences Limited Buyback Company Financials
All values are in ₹ Cr.
31-Mar-25 31-Mar-24
Profit After Tax -113.68 4.99
Total Borrowing 582.02 635.54
Total Revenue 1,674.97 1,698.66
Total Assets -- --
Net Worth 956.11 1,069.25
Reserves And Surplus 933.68 1,046.82
How to Participate in Nectar Lifesciences Limited Buyback?
Hold shares on Record Date
Firstly, to be eligible for the buyback the investor should have shares of Nectar Lifesciences Limited Buyback in Demat or physical form as on the record date Dec 24, 2025.
Tender via Broker or Exchange
Once you have shares in Demat, you can participate in the buyback process which is opening from Dec 31, 2025 by tendering your shares through your broker on BSE, NSE.
Receive Payment & Reversal
Then on TBA, the payment will be given to you for accepted shares and unaccepted shares will be returned to your Demat account.
Calculation of Investment in Nectar Lifesciences Limited Buyback Buyback 2026
Maximum market value of a share holder as on record date
₹200,000.00
Buyback price per share
₹27.00
Maximum share for small shareholders (200000 / 27)
7407.41 share
Closing price of stock as of 2025-12-03
Maximum amount invested in buyback (₹17.92 x 7407 shares)
₹132,740.74

* No. of shares stands to change according to the closing price on the record date

* For simplicity, we have considered the price on date Dec 3, 2025

Expected Profit from the Nectar Lifesciences Limited Buyback on the bases of acceptance Ratio:
Acceptance Ratio Amount Invested in Buyback No. of Shares Buyback Buyback Profit Profit%
33% ₹132,740.74 2444 22191 16.72%
50% ₹132,740.74 3703 33623 25.33%
75% ₹132,740.74 5555 50439 38.00%
100% ₹132,740.74 7407 67255 50.67%

Amount Invested in Buyback: ₹132,740.74

33% Acceptance Ratio
Shares Buyback: 2444
Buyback Profit: 22191
Profit %: 16.72%
50% Acceptance Ratio
Shares Buyback: 3703
Buyback Profit: 33623
Profit %: 25.33%
75% Acceptance Ratio
Shares Buyback: 5555
Buyback Profit: 50439
Profit %: 38.00%
100% Acceptance Ratio
Shares Buyback: 7407
Buyback Profit: 67255
Profit %: 50.67%
Nectar Lifesciences Limited Buyback - Necessity of the Objective

The buyback will help the company to return surplus cash to its shareholders holding equity shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders.
The buyback will help the company to optimize the capital structure;
The Buyback, which is being implemented through the Tender Offer route as prescribed under the SEBI Buyback Regulations, would involve allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved. The company believes that the reservation for small shareholders would benefit a large number of the Company's public shareholders, who get classified as small Shareholders, as per regulations 2(i)(n) of the SEBI Buyback Regulations.
The buyback may help in improving financial ratios like earnings per share, return on capital employed, and return on equity, by reduction in the equity base, thereby leading to long-term increase in shareholders' vlaue; and
The buyback gives an option to the shareholders holding Equity shares of the company, who can choose to participate and get cash in lieu of Equity shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the buyback offer, without additional investment.

Contact Details

Nectar Lifesciences Limited Buyback

Shop No. 5, SL Enclave, Behind Sohi HP Gas Agency, Barwala Road, Dera Bassi, Punjab, 140507

+91-0172-5078200

sales@neclife.com

https://www.neclife.com/

Registrar Contact Details

Kfin Technologies Ltd.

nectar.buyback@kfintech.com

04067162222, 04079611000

https://ipostatus.kfintech.com/